Biotech revenues hit $70 billion last year, as the pace of mergers and acquisitions picks up. For more, read this brief update, and listen to Ernst & Young's resident expert, Scott Sarazen. Ernst Young released its annual biotech review today.
Bloomberg - (BLOOM)
Apr. 17, 2007. 01:04 PM EST
60% premiums were paid for some technologies